Grünenthal press releases 2011

Aachen, December 21st 2011. “No time to rest in 2012” was one of the conclusions of the 6th CHANGE PAIN® Advisory Board meeting. The Board identified “Pain in the Elderly” as the next topic to be tackled by the initiative. Treating the elderly differs from treating younger patients as there are many physiological changes which have to be taken into account. The Advisory Board meeting took place in Munich early December with the goal of identifying challenges and shortcomings in pain therapy which need to be addressed in future.

Aachen, Germany, December, 12th 2011. Today the U.S. Food and Drug Administration (FDA) approved a reformulation of Endo Pharmaceuticals' Opana^® ER, an extended release opioid analgesic designed to be crush-resistant employing Grünenthal's proprietary INTAC™ Technology.

Aachen/Brussels, December 12th 2011. Pain as a multi-dimensional condition requires the involvement of a multidisciplinary team of healthcare professionals. The new practical guide “Towards a multidisciplinary team approach in pain management” provides guidance for healthcare professionals on how to set up a multidisciplinary team.

Aachen, December 2, 2011 – In his position as Vice President Corporate Legal, Marcus Heppner is in charge of the Corporate Legal Department of the internationally operating pain expert Grünenthal. He reports directly to Grünenthal Group CFO & COO Stefan Genten.

Aachen/Frankfurt, Germany. For the sixth year running, Grünenthal presented itself as contract manufacturer at the leading Convention on Pharmaceutical Ingredients and Intermediates, CPhI Worldwide.

Aachen/Hamburg, Germany,  29 September, 2011.  During the 7th Congress of the European Federation of the IASP^® Chapters (EFIC^®) in Hamburg (21-24 September), first insights from the European Road Map Monitor 2011 were presented.

"Research projects create confidence for positive changes and solutions in the area of pain"

Hamburg, September 22nd 2011. As pain concerns the everyday lives of millions of people worldwide, understanding its mechanisms is crucial to improve patients’ conditions and treatments. In line with this thought, five former winners of the EFIC-Grünenthal Grant (E-G-G) presented insights into the development and progress of their projects at the show case symposium “New Findings in Clinical Pain Research” during the 7th EFIC® Congress in Hamburg, Germany.

Aachen/Hamburg, Germany, 12 September, 2011.  During the 7th Congress of the European Federation of the IASP^® (International Associations for the Study of Pain) Chapters (EFIC^®) in Hamburg between September 21-24, first insights on the strategic international and national implementation of a European “Road Map for Action” for  improved pain care in Europe will be presented.

Aachen, August 24, 2011. Grünenthal‘s focus on pain therapy is paying off: Core business in the first half of 2011 grew by 9% compared to the previous year / strengthened presence in Latin America

Aachen, Germany, 26 August, 2011. Today the German pharmaceutical company Grunenthal, which is known for its expertise in pain medicines, announced that the U.S. Food and Drug Administration (FDA) has approved tapentadol extended-release tablets for the management of moderate to severe chronic pain in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.